Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production
J A Mikovits 1 , H A Young, P Vertino, J P Issa, P M Pitha, S Turcoski-Corrales, D D Taub, C L Petrow, S B Baylin, F W Ruscetti Affiliation Intramural Research Support Program, SAIC Frederick, Division of Basic Sciences, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick Maryland 21702-1201, USA.
Mikovits @ fcrfv1. ncifcrf .gov
National Library of Medicine National Center for Biotechnology Information MikovitsJA.
In this affidavit, I summarize under oath and penalty of perjury some points also described in said book as a work derivative to my book, for the use with my permission in this law suit concerning the COVID-19 Coronavirus while preserving all rights in the book.
55. I entered professional science from the University of Virginia with a Bachelor of Arts degree in chemistry on June 10, 1980.
56.I began as a protein chemist for the National Cancer Institute (NCI) working on a life-saving project to purify interferon: the first immune therapy for cancer and infectious disease.
57.I was part of the team that developed immunotherapy interferon-alpha. That therapy was on the cover of Time Magazine, March 31, 1980 as the big "If", a magic bullet to cancer. Can we take our own biological response modifiers and our own immune system and reeducate it to prevent or treat infectious disease? 58.At the time that was just before the discovery of HIV AIDS but after the discovery by my lifelong mentor, Dr. Francis Ruscetti, who in 1980isolatedthe first cancer-causing human retrovirus, HTLV-1.
59.I am a biochemist and molecular biologist who worked in top government laboratories developing treatments for Ebola, HIV, and coronaviruses like SARS.
60.I have worked professionally for 40 years in immunology and virology.
61.I was recognized by colleagues and superiors in this work for high-quality work 9ThriftBooks 5as well as Amazon and almost everywhere. 62.In 1999, I reached the apex of the then male-dominated world of scientific research, when I was chosen to direct the Lab of Antiviral Mechanisms in the Screening Technologies branch of the NCI’s Division of Cancer Treatment.
63.Part of my research –similar to the challenges of COVID-19 today –involved the biological response modifiers in 1983 and literally from that day one studied from the patient level why people got sick --why some got AIDS from HIV and other people could be perfectly healthy, never knowing they even had the infection.
64.My PhD. thesis in 1991 changed thetreatment paradigm of HIV. It was a subset of immune cells known as monocyte macrophages, which had to be targeted with drug therapy Plague of Corruption: Restoring Faith in the Promise of Science (Children’s Health Defense) https://www.amazon.co.uk/Plague-Corru...
mirrored from Valuetainment added proofs
Debunking the Narrative With Prof Dolores Cahill
Prof. Dolores J. Cahill, of Translational Science at UCD School of Medicine, University College Dublin has over 25 years expertise in high-throughput protein array, antibody array, proteomics technology development,automation and their biomedical applications, including in biomarker discovery, diagnostics and personalised medicine.
She is Professor of Translational Science, and at the Conway Institute at the University College Dublin (UCD) (2005-present). With her research group & collaborators, she has achieved key breakthroughs in developing and demonstrating applications of high throughput array technology in biological, diagnostics & medical research.
Prof. Cahill pioneered this research at the Max-Planck-Institute of Molecular Genetics in Berlin, Germany (1996-2003) and holds several granted international patents in this vital field. Some of her activities include: In 1996, she co-founded Protagen AG (https://protagen.com/) in Dortmund, including with Prof. Helmut Meyer, as a spin-out of the Max-Planck-Institute to commercialise her discoveries.
Protagen Protein Services (https://protagenproteinservices.com/) a 2014 spin-off company of Protagen delivers expert protein, antibody, proteomics & peptide contract services to the pharmaceutical industry & health care sectors. Both companies have advanced these technologies & applications; Protagen has screened and profiled the autoantibody repertoire of over 20,000 patients (https://protagen.com/data-and-insight...). Protagen AG and Protagen Protein Services have over 200 employees in 2018.
Since 2016, Prof. Cahill is a shareholder & Advisory Board member of Atturos Ltd, Prof. Stephen Pennington’s UCD spin-out company nvolved in improved Prostate Cancer diagnosis (http://atturos.com/ and http://atturos.com/company/advisors/).
On obtaining her PhD, she obtained an EU ‘Human Capital & Mobility’ Post-doctoral Fellowship at the Technical University, Munich, Germany (1994-1995).
Prof. Cahill became Group Leader of the Protein Technology Group in the Max-Planck-Institute of Molecular Genetics, Berlin (1996-2003). She obtained an Associate Professor position, in the Department of Clinical Pharmacology and Director of Proteomics Core, RCSI, Dublin (2000-2005).
Since 2005 – present, she is Full Professor of Translational Science in the School of Medicine, University College Dublin She has extensive management experience, including successfully obtaining funding from the European Commission (FP4, FP5, FP6, FP7 and Horizon 2020), Science Foundation Ireland, Enterprise Ireland, Health Research Board , project managing, publishing & reporting on all financial & regulatory aspects in academic & private sectors, She has over 100 peer reviewed publications, with over 5000 citations and a H-index is 31, which is in the top 10% globally for the Biomedicine discipline.
Prof. Cahill is internationally recognised for her biomedical research, publications and patent record in life sciences, biotechnology, personalised healthcare, personalised medicine, diagnostics, biomarker discovery and validation, proteomics, biotechnology, high content protein and antibody arrays and their biomedical, diagnostic and clinical applications. Her publications have demonstrated utility and applications in the research, commercial & clinical sectors and include characterisation of antibodies specificity (including therapeutic antibodies), biomarker discovery, diagnostics, assay development, protein-interaction studies, proteomics, large scale/systems biology research, project managing, publishing & reporting on all financial & regulatory aspects in academic & private sectors, validating biomarker panels in diagnostic clinical trial, personalised medicine and assessing immune related adverse events.
She has given over 100 Keynotes Lectures in Ireland, UK, Europe, USA, China, Japan, South Korea, Australia, South America. For example, she is invited to the ‘5th Precision Medicine and Biomarkers Leaders’ Summit’ in Munich in September & will Chair a Round-table on Personalised Medicine and Adverse Events to discuss whether lessons can be learned from cancer immunotherapy and immune related adverse events understanding insight leads to discovery's of predictive biomarkers , adverse events
[ Prof. Dolores J. Cahill on Del Bigtree ]
bitchute @ backup